LSDMescaline

Effects of mescaline and lysergic acid (d-LSD-25)

This early clinical study (1952) investigated the effects of mescaline (0.4 -; 0.6g) and LSD (10-120μg) in patients with schizophrenia (n=59 & 21) and found that it aggravated their symptoms and made their psychic integration even more disorganized compared to healthy individuals.

Authors

  • Cattell, J. P.
  • Hoch, P. H.
  • Pennes, H. H.

Published

American Journal of Psychiatry
individual Study

Abstract

Methods: The effects of mescaline and lysergic acid were studied in schizophrenic patients.Results: It was found that physiological changes were produced in these patients and that their mental symptomatology was markedly aggravated.Discussion: The observations made with the above-mentioned drugs on normal individuals were compared with those seen in schizophrenic patients. Mescaline and lysergic acid are drugs that disorganize the psychic integration of a person. This disorganization is much more apparent in schizophrenics than in normals. The diagnostic, prognostic, and therapeutic use of these drugs is also discussed.

Unlocked with Blossom Pro

Research Summary of 'Effects of mescaline and lysergic acid (d-LSD-25)'

Study Details

Cited By (12)

Papers in Blossom that reference this study

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

Böge, K., Correll, C. U., Curtis, L. et al. · Molecular Psychiatry (2024)

Psychiatric risks for worsened mental health after psychedelic use

Carhart-Harris, R. L., Erritzoe, D., Kettner, H. et al. · Journal of Psychopharmacology (2024)

41 cited
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

González-Maeso, J., Jaster, A. M. · Molecular Psychiatry (2023)

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

Arikci, D., Becker, A. M., Coviello, F. et al. · Neuropsychopharmacology (2023)

Mescaline: The forgotten psychedelic

Campbell, I., Dyck, J., Narine, K. et al. · Neuropharmacology (2022)

Psychedelic drugs and perception: a narrative review of the first era of research

Aday, J. S., Bloesch, E. K., Davoli, C. C. et al. · Reviews In The Neuroscience (2021)

Psychiatry & the psychedelic drugs. Past, present & future

Iliff, J., Nutt, D. J., Rucker, J. · Neuropharmacology (2017)

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Halberstadt, A. L. · Behavioural Brain Research (2014)

Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

Brugger, S., Carhart-Harris, R. L., Nutt, D. J. et al. · Journal of Psychopharmacology (2013)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Kometer, M., Vollenweider, F. X. · Nature Reviews Neuroscience (2010)

Show all 12 papers
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines

Winter, J. C. · Psychopharmacology (2008)

Autistic Schizophrenic Children: An Experiment in the Use of D-Lysergic Acid Diethyladmide (LSD-25)

Freedman, A. M. · JAMA Psychiatry (1962)

Your Library